HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8⁺ T and NK cells: a novel therapeutic tumour vaccine.

ABSTRACT:

Background

CD8⁺ T cell-mediated adaptive cellular immunity and natural killer (NK) cell-mediated innate immunity both play important roles in tumour immunity. This study aimed to develop therapeutic tumour vaccines based on double-activation of CD8⁺ T and NK cells.

Methods

The immune Epitope database, Molecular Operating Environment software, and enzyme-linked immunosorbent assay were used for epitope identification. Flow cytometry, confocal microscopy, UPLC-QTOF-MS, and RNA-seq were utilized for evaluating immunity of PBMC-derived DCs, CD8⁺ T or NK cells and related pathways. HLA-A2.1 transgenic mice combined with immunologically reconstituted tumour-bearing mice were used to examine the antitumour effect and safety of epitope vaccines.

R

SUBMITTER: Yu Z 

PROVIDER: S-EPMC8082934 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature